



(12) Translation of
European patent specification

(11) NO/EP 2827860 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/415 (2006.01)
A61P 11/00 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2017.01.30
(80)	Date of The European Patent Office Publication of the Granted Patent	2016.10.26
(86)	European Application Nr.	13710851.0
(86)	European Filing Date	2013.03.19
(87)	The European Application's Publication Date	2015.01.28
(30)	Priority	2012.03.20, US, 201261613187 P
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
(73)	Proprietor	Mereo BioPharma 1 Limited, 1 Cavendish Place, London W1G 0QF, GB- Storbritannia
(72)	Inventor	FORD, Paul Andrew, c/o Novartis Pharmaceuticals UK Limited, Wemblehurst Road,, Horsham, West Sussex, Sussex RH12 5AB, GB-Storbritannia
(74)	Agent or Attorney	Bryn Aarflot AS, Postboks 449 Sentrum, 0104 OSLO, Norge

(54)	Title	USE OF A PYRAZOLE DERIVATIVE IN THE TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
(56)	References Cited:	WO-A1-2005/009973 WO-A2-2007/096151 IKEDA A ET AL: "PHARMACOLOGICAL TREATMENT IN ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE", DRUGS & AGING, ADIS INTERNATIONAL LTD, NZ, vol. 12, no. 2, 1 January 1998 (1998-01-01), pages 129-137, XP000986468, ISSN: 1170-229X WANG HAIFENG ET AL: "Effect of sequential treatment with syndrome differentiation on acute exacerbation of chronic obstructive pulmonary disease and AECOPD Risk-Window: study protocol for a randomized placebo-controlled trial", TRIALS, BIOMED CENTRAL, LONDON, GB, vol. 13, no. 1, 20 April 2012 (2012-04-20) , page 40, XP021125428, ISSN: 1745-6215, DOI: 10.1186/1745-6215-13-40

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

PATENTKRAV

- 5 1. 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyklopropyl-4-metylbenzamid eller et farmasøytisk akseptabelt salt, hydrat eller solvat derav for anvendelse ved behandling av akutte forverringar av kronisk obstruktiv pulmonal sykdom.
2. Enkeltdose av 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyklopropyl-4-
10 metylbenzamid eller et farmasøytisk akseptabelt salt, hydrat eller solvat derav for anvendelse i behandling av akutte forverringar av kronisk obstruktiv pulmonal sykdom.
3. Oralt farmasøytisk preparat som inneholder 3-[5-amino-4-(3-cyanobenzoyl)-
15 pyrazol-1-yl]-N-cyklopropyl-4-metylbenzamid eller et farmasøytisk akseptabelt salt, hydrat eller solvat derav for anvendelse i behandlingen av akutte forverringar av kronisk obstruktiv pulmonal sykdom.
4. Farmasøytisk sammensetning for anvendelse i henhold til krav 3 som
20 inneholder 50 til 100 mg 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl] -N-cyklopropyl-4-metylbenzamid eller et farmasøytisk akseptabelt salt, hydrat eller solvat derav.
5. Farmasøytisk sammensetning for anvendelse i henhold til krav 4, som
25 inneholder 60 til 90 mg 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyklopropyl-4-metylbenzamid eller et farmasøytisk akseptabelt salt, hydrat eller solvat derav.
6. Farmasøytisk sammensetning for anvendelse i henhold til krav 5, som
inneholder 75 mg 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyklopropyl-4-
30 metylbenzamid eller et farmasøytisk akseptabelt salt, hydrat eller solvat derav.
7. Farmasøytisk sammensetning for anvendelse i henhold til krav 6, som
inneholder 75 mg 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyklopropyl-4-
metylbenzamid i sin frie form.

8. Farmasøytisk sammensetning for anvendelse i henhold til krav 3 i form av en tablett.
9. Farmasøytisk sammensetning for anvendelse i henhold til krav 7 i form av en tablett.